| 10.51 -0.75 (-6.66%) | 05-29 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 14.54 | 1-year : | 16.98 |
| Resists | First : | 12.44 | Second : | 14.54 |
| Pivot price | 9.71  |
|||
| Supports | First : | 7.54 | Second : | 4.51 |
| MAs | MA(5) : | 10.34 |
MA(20) : | 8.76 |
| MA(100) : | 6.17  |
MA(250) : | 10.04 |
|
| MACD | MACD : | 1.2 |
Signal : | 1.1 |
| %K %D | K(14,3) : | 76.7 |
D(3) : | 72.5 |
| RSI | RSI(14): 65.4 |
|||
| 52-week | High : | 19.14 | Low : | 3.92 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ATRA ] has closed below upper band by 22.1%. Bollinger Bands are 43.1% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 11.29 - 11.35 | 11.35 - 11.4 |
| Low: | 10.23 - 10.29 | 10.29 - 10.34 |
| Close: | 10.41 - 10.51 | 10.51 - 10.61 |
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
Fri, 22 May 2026
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
Thu, 21 May 2026
ATRA Stock Shoots Up 82% in a Month: Here's What You Should Know - TradingView
Tue, 19 May 2026
Atara Biotherapeutics, Inc. (ATRA) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 9 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 16.7 (%) |
| Held by Institutions | 48.8 (%) |
| Shares Short | 306 (K) |
| Shares Short P.Month | 327 (K) |
| EPS | -1.23 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -4.39 |
| Profit Margin | -41 % |
| Operating Margin | -653 % |
| Return on Assets (ttm) | 11.1 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | -99.5 % |
| Gross Profit (p.s.) | -0.32 |
| Sales Per Share | 2.71 |
| EBITDA (p.s.) | 0.89 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -26 (M) |
| Levered Free Cash Flow | -6 (M) |
| PE Ratio | -8.62 |
| PEG Ratio | 0 |
| Price to Book value | -2.4 |
| Price to Sales | 3.86 |
| Price to Cash Flow | -3.46 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|